FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues.
Autoimmune Disorders
Genentech eyes lupus market for Gazyva with positive Phase III data readout
FDA adds boxed warning to multiple sclerosis drugs after anaphylaxis cases
Candid Therapeutics signs $925m T-cell engager deal with WuXi Biologics
CHMP recommends oral peanut allergy immunotherapy treatment for toddlers
Advanz Pharma’s liver disease drug pulled from European market after court hearing
FDA grants breakthrough status to J&J’s nipocalimab for SjD treatment
Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets
